PRESS RELEASES

OriGene Technologies Announces 37,000 ORF cDNA Clones in GFP Vector
Rockville, MD. Oct. 23, 2008 – OriGene Technologies, Inc. announces its flagship products, TrueORF cDNA clones, are available now in GFP (green fluorescence protein) vector, enabling easy transfection monitoring and protein expression. With this launch, over 25,000 human ORF (open reading frame) clones and 12,000 mouse ORF clones can be ordered in pCMV-tGFP vector. (Press Release)

OriGene Technologies Launches 5,000 Human Antigen Standards for Antibody Validation
Rockville, MD. September 15, 2008 – OriGene Technologies, Inc. announces it has launched a new product line for antibody validation - VERIFY Tagged Antigen™ - a collection of tagged over-expression cell lysates to be used as Western blot standards. The offering covers 5,000 over-expressed human proteins, each with a built-in C-terminal Myc/DDK tag for easy expression verification and antibody validation. (Press Release)

OriGene's Functional Kinome Collection Published in Cell
Rockville, MD. May 2nd, 2008 Scientists from University of Helsinki, Institute of Molecular Medicine in Finland and OriGene Technologies joined effort in creating the most comprehensive kinome collection of nearly all predicted human protein kinases, including the functional kinases and their kinase-deficient counterparts. Equipped with this collection, the authors successfully identified novel kinase regulators in Hedgehog signaling pathway and in activation of Karposi’s Sarcoma herpesvirus. The results are published in May 2nd issue of Cell, titled “Application of active and kinase-deficient kinome collection for identification of kinase regulating Hedgehog signaling”. (Press Release)

Novartis Scientists Discovered Novel Activators of PGC-1a Transcription Using 10,000 Human Full-length cDNA clone Array developed by OriGene
Rockville, MD. September 26, 2006 –Novartis scientists have published their use of OriGene’s TrueClone^TM full-length cDNA collection to identify novel activators of PGC-1atranscription. This work was recently published in the Journal Proceedings of the National Academy of Sciences titled “Transducer of regulated CREB-binding proteins (TORCs) induces PGC-1a transcription and mitochondrial biogenesis in muscle cells” (PNAS, September 26, 2006 vol. 103 no.39 14379-14384). PGC-1alpha is a co-activator of PPAR-gamma and regulator of adaptive thermogenesis. Novel activators like TORCs can serve as potential therapeutic targets to modulate mitochondrial function which is implicated in many human diseases.

Genentech Acquires Access to the OriGene TrueClone^TM Collection
March 28, 2006 – OriGene Technologies Inc. announced that Genentech has purchased their TrueClone^TM Collection of full-length human cDNAs suitable for transfection and direct in vitro expression for internal research and development.

Bayer HealthCareAcquires OriGene’s TrueClone^TM cDNAs for Functional Analyses
March 13, 2006 – OriGene Technologies Inc. today announced that Bayer HealthCare AG has acquired access to OriGene’s collection of authentic full-length cDNA clones.
"Having access to a comprehensive array of cDNA clones is of utmost importance in today's gene or protein-based research labs," said Ulf Brüggemeier, Director, Target Research of Bayer HealthCare, Pharmaceuticals. "We believe that the OriGene cDNA collections are uniquely able to provide us with the necessary content to support the drug-related research and diagnostic projects across Bayer HealthCare."

OriGene and Cytomyx Collaborate to Develop New Biomarker Validation Technologies
October 17, 2005 – OriGene Technologies Inc. today announced they have entered into an agreement with Cytomyx Holdings, PLC to co-develop new tools to profile gene expression and biomarker validation in a range of human cancers.

Eisai London Research Laboratories Licenses OriGenes FlagArray^TM for Genome-Wide Functional Analyses
August 2, 2005 - OriGene Technologies Inc. today announced that Eisai London Research Laboratories has licensed OriGenes FlagArray platform for high-throughput drug target discovery. "We are pleased to formalize our relationship with OriGene, said Yukio Nishizawa, PhD, Director of Research for Eisai London Research Labs. We believe OriGenes FlagArray to be an innovative technology that will prove an excellent platform for use in our discovery programs."

OriGene to Collaborate with Massachusetts General Hospital to use OriGenes Large, Full-length cDNA Collection (FlagArray^TM) for Genome-Wide Functional Analyses
July 25, 2005 - OriGene Technologies Inc. today announced a collaboration with the laboratory of Dr. Brian Seed at the MGH to use OriGenes FlagArray platform for high-throughput functional analysis of genes. "OriGene has done a wonderful job in creating an outstanding collection of high quality cDNAs in a single expression vector, said Brian Seed, PhD, We believe OriGene's FlagArray will be an extremely useful resource to help us accelerate our understanding of the function and role of genes in biology in a high throughput and systematic manner."

Regeneron Pharmaceuticals Licenses OriGene TrueClone^TM Collection
April 26, 2005 - OriGene Technologies Inc. today announced that Regeneron Pharmaceuticals has licensed a subscription based access to their TrueClone^TM Collection of 24,000 full-length human cDNAs suitable for transfection and high throughput functional analyses. "We are pleased to formalize our relationship with OriGene, said Drew Murphy, Vice President of Target Discovery for Regeneron. We believe that full-length cDNAs isolated from cDNA libraries are the most reliable source of authentic coding regions for our critical applications. The OriGene True Clone collection has proven to be an excellent source of full-length human cDNAs for use in Regeneron's protein expression and target validation platforms."

Novasite Pharmaceuticals Acquires Access to the OriGene TrueClone^TM Collection
February 15, 2005 - OriGene Technologies Inc. today announced that Novasite Pharmaceuticals has licensed a subscription access to their TrueClone^TM Collection of 24,000 full-length human cDNAs suitable for transfection and high throughput functional analyses. "We are pleased to formalize our relationship with OriGene. We have found their TrueClone collection to be the best answer to expanding needs within the pharmaceutical industry to access readily available full-length human cDNAs for multiple drug targets in a timely and reliable manner, said Juan Ballesteros, Chief Scientific Officer of Novasite. The OriGene TrueClone collection will complement our endogenously expressed receptor cell lines and jumpstart our programs to screen families of GPCRs for allosteric modulators."

MacroGenics to License Novel Monoclonal Antibody Target from OriGene
October 19, 2004 - OriGene Technologies Inc. and MacroGenics, Inc. announced today that the companies have entered into a license agreement for a cancer target initially identified with OriGenes HTP-Rapid-ScanTM technology. MacroGenics has the exclusive right to develop compounds against the target under the terms of their collaboration and will focus on the development of therapeutic monoclonal antibody candidates to this molecule. In exchange, OriGene will be entitled to receive various option fees, milestones and royalty payments as the compounds are developed and commercialized.

OriGene Technologies Awarded NHGRI Grant to Isolate 400 Very Large Full-Length Genes for Addition to TrueCloneTM Collection
September 23, 2004 - OriGene Technologies Inc., a privately held company currently providing the worlds largest collection of 22,000 authentic full-length cDNA clones (TrueCloneTM), announced today that it has received a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health through the National Human Genome Research Institute (NHGRI).

Structural Genomics Consortium Gains Access to the OriGene TrueClone Collection for Structural Genomics Program
Rockville, MD. August 10, 2004 - OriGene Technologies Inc. today announce that Structural Genomic Consortium located at Oxford University and University of Toronto has access to the TrueClone Collection of over 22,000 non-redundant full-length human cDNA clones for use in their structural genomics program.

Xantos Biomedicine Acquires the OriGene TrueClone Collection for HTP Screening
Rockville, MD. August 9, 2004 - OriGene Technologies Inc. announced Xantos Biomedicine in Germany has acquired access to their TrueClone Collection of non-redundant full-length human cDNA clones. Xantos uses its proprietary High-Throughput Cellular Screening Technology, XantoScreen and the full-length human clone collection to identify and functionaly validate novel targets.

RIKEN Acquires the OriGene TrueClone Collection for Structural Proteomics Program
Rockville, MD. March 30, 2004 OriGene Technologies Inc. today announced the purchase of the TrueClone Collection of over 20,000 non-redundant full-length human cDNA clones by the RIKEN Protein Research Group (PRG) for use in their structural proteomics and related protein functional analysis programs.

Genomics Institute of the Novartis Research Foundation Acquires the OriGene TrueClone Collection for High-Throughput Drug Target Discovery
Rockville, MD. March 9, 2004 OriGene Technologies Inc. today announced the purchase of the TrueClone Collection of over 20,000 non-redundant full-length human cDNA clones by the Genomics Institute of the Novartis Research Foundation (GNF) for use in high-throughput discovery efforts.

OriGene Adds Nuclear Hormone Receptor CloneSet to TrueClone Collection
Rockville, MD. February 24, 2004 OriGene Technologies Inc today announced the addition of the NHR (Nuclear Hormone Receptor) CloneSet, a designated subset of 70 full-length nuclear hormone receptor cDNA clones, to their TrueClone Collection product line.

OriGene Adds GPCR CloneSet to TrueClone Collection
Rockville, MD. December 10, 2003 OriGene Technologies Inc today announced the addition of the GPCR CloneSet, a designated subset of over 300 full-length human non-olfactory G protein-coupled receptors, to the TrueClone Collection product line. The GPCR CloneSet is the largest commercial cDNA source of this pharmaceutically important gene family, thus enabling a system biology approach to drug-potency, drug-toxicity and ligand identification studies.

OriGene Adds Protein Kinase CloneSet to TrueClone Collection
Rockville, MD. November 4, 2003 OriGene Technologies Inc today announced the addition of the Kinase CloneSet, a designated subset of over 500 full-length kinase cDNA clones, to their TrueClone Collection product line. The Kinase CloneSet approaches the predicted 518 putative genes in the Kinome (Manning, G. et al., Science 298:1912, 2002) and represents the largest commercial source of full-length human kinase genes.

OriGene and Tanox Establish Research Collaboration
Rockville, MD. October 7, 2003 OriGene Technologies Inc today announced a research collaboration with Tanox Inc (NASDAQ TNOX) for the functional study of 2,000 full-length human cDNA clones encoding membrane bound proteins. Tanox will reserve the rights for therapeutic applications identified through this collaboration. OriGene will retain the rights for research and diagnostic reagent development.